Marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes, is a dual GLP-1 and GIP receptor agonist that offers significant benefits for weight management. Here’s a concise overview of its benefits for weight loss, based on available data:
 
Substantial Weight Reduction: Clinical trials, such as SURMOUNT-1, demonstrate that tirzepatide leads to significant weight loss. Patients on 15 mg weekly lost an average of 23.6 kg (52.0 lb), those on 10 mg lost 22.2 kg (48.9 lb), and those on 5 mg lost 16.1 kg (35.5 lb) after 72 weeks, compared to 2.4 kg (5.3 lb) with placebo. Some trials report up to 20–26.6% body weight reduction when combined with lifestyle changes like diet and exercise.
Appetite Suppression: Tirzepatide reduces hunger by activating GLP-1 receptors, which signal satiety in the brain, leading to lower calorie intake. It also slows gastric emptying, helping you feel full longer after meals.
Improved Metabolic Health: Beyond weight loss, tirzepatide enhances insulin sensitivity, stabilizes blood sugar levels, and reduces metabolic risk factors like waist circumference, blood pressure, and lipid levels, contributing to overall cardiovascular health.
Sustained Results: Long-term data, including 3-year outcomes from SURMOUNT-1, show sustained weight loss (e.g., 22.9% or 54 lbs on average) when combined with lifestyle interventions, with 94% reduced risk of progressing to diabetes in at-risk individuals.
Dual Hormone Action: Unlike single GLP-1 agonists like semaglutide, tirzepatide’s dual action on GLP-1 and GIP receptors enhances weight loss efficacy, often outperforming other medications in head-to-head trials like SURMOUNT-5.